Exploring the effects of blue light on vagus nerve stimulation for epilepsy treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how exposure to blue light may enhance the effects of vagus nerve stimulation (VNS) in patients suffering from refractory epilepsy. VNS is an established treatment, but many patients do not experience sufficient relief from their seizures. By examining various biomarkers associated with VNS action, the study aims to determine if blue light can improve the efficacy of this treatment. The methodology includes the use of electroencephalography, electrocardiograms, and other assessments to monitor the effects of light exposure on patients with VNS implants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients:

VNS implanted since at least 3 months age \>18-60 years; IQ \>55 on Wechsler scale (normal status or mild cognitive impairment)

healthy participants aged between 18 and 35 years without any medical history (neurological / psychiatric disease)

Exclusion criteria:

Patients:

other medical implanted devices than VNS, ocular diseases

Helthy participants:

medical implanted devices, cerebral trauma, ocular disease

Where it's running

• Cliniques Universitaires Saint Luc
  Woluwe-Saint-Lambert, Belgium Recruiting

Study contacts

• Study coordinator: Inci / cakiroglu
• Email: inci.cakiroglu@uclouvain.be
• Phone: +32470612917

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biomarker study to predict Vagus Nerve Stimulation response in adults with refractory epilepsy

  This study tests whether biomarkers and network measures can predict how adults with refractory epilepsy will respond to vagus nerve stimulation (VNS) after implantation.

  Recruiting Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Brussels · NCT07909486

• Cannabidiol as add-on therapy for children with refractory epilepsy (CBD-uN1que): an individualized N-of-1 series

  This trial tests whether CBD oil helps reduce seizures in children with hard-to-treat epilepsy, using a series of personalized N-of-1 comparisons against a placebo.

  Recruiting Phase 3 UMC Utrecht · Utrecht, Utrecht · NCT07668856

• Real-world use of the OneRF Ablation System for epilepsy

  This registry collects real-world outcomes and device performance from patients with drug-resistant epilepsy who are treated with SEEG-guided RF ablation using the OneRF system.

  Recruiting at 3 sites NeuroOne Medical Technologies Corporation · Miami, Florida and 2 other locations · NCT07546253

• Investigating white matter fibers in the brain during wakefulness and sleep

  This study is testing how sleep affects the connections in the brain's white matter for people aged 14-65 with drug-resistant epilepsy to help improve treatment options.

  Recruiting Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT06524479

• One-of-a-kind self‑administered web music therapy for epilepsy

  This test sees if daily listening to specific music through a web app can reduce epileptic brain activity in adults with medication‑resistant focal epilepsy who have an RNS implant.

  Recruiting Dartmouth-Hitchcock Medical Center · Worcester, Massachusetts and 1 other locations · NCT06425029

• Optimizing brain stimulation for epilepsy treatment

  This study is testing if adjusting the settings of brain stimulation devices can help people with hard-to-treat epilepsy have fewer seizures.

  Recruiting Early Phase 1 University of Minnesota · Minneapolis, Minnesota · NCT05493722

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.